MX2013011184A - Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades. - Google Patents

Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.

Info

Publication number
MX2013011184A
MX2013011184A MX2013011184A MX2013011184A MX2013011184A MX 2013011184 A MX2013011184 A MX 2013011184A MX 2013011184 A MX2013011184 A MX 2013011184A MX 2013011184 A MX2013011184 A MX 2013011184A MX 2013011184 A MX2013011184 A MX 2013011184A
Authority
MX
Mexico
Prior art keywords
diagnosing
compositions
treating
methods
monitoring disease
Prior art date
Application number
MX2013011184A
Other languages
English (en)
Other versions
MX352296B (es
Inventor
Richard Morgan
Original Assignee
Hox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hox Therapeutics Ltd filed Critical Hox Therapeutics Ltd
Publication of MX2013011184A publication Critical patent/MX2013011184A/es
Publication of MX352296B publication Critical patent/MX352296B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Las composiciones y los métodos con los cuales se puede inhibir la expresión del gen de la proteína TMEM92 o que inhiben la función de la proteína TMEM92 de muerte pueden utilizarse para tratar, diagnosticar y vigilar enfermedades, por ejemplo, cáncer.
MX2013011184A 2011-03-28 2012-03-28 Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades. MX352296B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1105129.9A GB201105129D0 (en) 2011-03-28 2011-03-28 Compositions and methods for treating, diagnosing and monitoring disease
PCT/GB2012/000285 WO2012131301A1 (en) 2011-03-28 2012-03-28 Compositions and methods for treating, diagnosing and monitoring disease

Publications (2)

Publication Number Publication Date
MX2013011184A true MX2013011184A (es) 2014-03-12
MX352296B MX352296B (es) 2017-11-17

Family

ID=44067442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011184A MX352296B (es) 2011-03-28 2012-03-28 Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.

Country Status (16)

Country Link
US (1) US9803196B2 (es)
EP (1) EP2691526B1 (es)
JP (1) JP6158785B2 (es)
KR (1) KR20140045345A (es)
CN (1) CN103502453B (es)
AU (1) AU2012235986B2 (es)
BR (1) BR112013025113A2 (es)
CA (1) CA2831481A1 (es)
DK (1) DK2691526T3 (es)
ES (1) ES2635393T3 (es)
GB (1) GB201105129D0 (es)
IL (1) IL228581A (es)
MX (1) MX352296B (es)
RU (1) RU2013143373A (es)
WO (1) WO2012131301A1 (es)
ZA (1) ZA201307890B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108085388B (zh) * 2017-12-27 2020-04-10 固安博健生物技术有限公司 一种与骨肉瘤发生发展相关的基因及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507549B2 (en) * 1997-03-07 2009-03-24 Siemens Healthcare Diagnostices, Inc. Method for following the progress of prostate cancer
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2005000087A2 (en) 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
WO2002078516A2 (en) 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
US20040198651A1 (en) * 2001-04-20 2004-10-07 Klammer Aaron A. Secreted proteins
JP2003135075A (ja) 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
CA2682899A1 (en) * 2007-04-12 2008-10-23 Proteosys Ag Autoimmune regulation of prostate cancer by annexin a3
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
EP2177615A1 (en) * 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases

Also Published As

Publication number Publication date
MX352296B (es) 2017-11-17
AU2012235986B2 (en) 2017-05-04
GB201105129D0 (en) 2011-05-11
KR20140045345A (ko) 2014-04-16
CN103502453A (zh) 2014-01-08
ES2635393T3 (es) 2017-10-03
CN103502453B (zh) 2017-06-09
JP2014511845A (ja) 2014-05-19
JP6158785B2 (ja) 2017-07-05
US20140154238A1 (en) 2014-06-05
EP2691526A1 (en) 2014-02-05
BR112013025113A2 (pt) 2016-11-22
NZ615915A (en) 2015-08-28
WO2012131301A1 (en) 2012-10-04
AU2012235986A1 (en) 2013-10-17
CA2831481A1 (en) 2012-10-04
EP2691526B1 (en) 2017-05-10
US9803196B2 (en) 2017-10-31
ZA201307890B (en) 2014-07-30
IL228581A0 (en) 2013-12-31
IL228581A (en) 2017-07-31
RU2013143373A (ru) 2015-05-10
DK2691526T3 (en) 2017-08-28

Similar Documents

Publication Publication Date Title
AU2019232913A1 (en) Methods and processes for non-invasive assessment of genetic variations
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
PH12014501844B1 (en) Peptidomimetic macrocycles
PH12015500433B1 (en) Methods and compositions for treatment of a genetic condition
MX2015011774A (es) Biomarcadores y metodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
EA201171367A1 (ru) Винилиндазолильные соединения
WO2012166626A8 (en) Reagents and methods for treating dental disease
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
SG10201808463RA (en) Methods for high throughput receptor:ligand identification
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
MX2014009750A (es) Composiciones antifungicas para el tratamiento de piel y uñas.
EP3693742A3 (en) Methods of detecting prostate cancer
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
PH12015500223B1 (en) Method for manufacturing low-protein rice and food using low-protein rice
MX2020011946A (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda).
WO2013132354A3 (en) Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer

Legal Events

Date Code Title Description
FG Grant or registration